BX-912 化学構造
分子量: 471.35

高品質保証

カスタマーフィードバック(1)

MSDS

製品説明

  • Compare PDK-1 Inhibitors
    PDK-1製品生物活性の比較
  • 研究分野

製品の説明

生物活性

製品説明 BX-912は選択的な強力なPDK1阻害剤で、 IC50 が 12 nMになる。
ターゲット PDK1
IC50 12 nM [1]
In vitro試験 BX912 prevents ChcK1, PKA, c-kit, and KDR with IC50 of 0.83, 0.11, 0.85, and 0.41 μM, resepectively. BX912 blocks PDK1/Akt signaling in tumor cells and suppresses the anchorage-dependent growth of a variety of tumor cell lines (such as PC-3 cells ) in culture or induces apoptosis. A number of cancer cell lines (such as MDA-468 breast cancer) with elevated Akt activity are >30-fold more sensitive to growth inhibition by PDK1 inhibitor BX912 in soft agar than on tissue culture plastic, consistent with the cell survival function of the PDK1/Akt signaling pathway, which is particularly important for unattached cells. BX912 potently blocks PDK1 enzyme activity in a direct kinase assay format, although BX912 fails to block preactivated AKT2 activity (IC50 > 10 μM). Therefore, BX-912 is a direct inhibitor of PDK1. BX912 is a competitive inhibitor of PDK1 activity with respect to its substrate, ATP, suggesting that BX912 binds to the ATP binding pocket of PDK1. The aminopyrimidine backbone of BX912 adopts a similar orientation in the active site of PDK1. BX912 promotes a pronounced increase in the population of MDA-468 cells with 4 N DNA content, indicative of a block at the G2/M phase of the cell cycle. BX912 also potently inhibits the growth of HCT-116 cells in soft agar, showing a 96% inhibitory effect at a dose of 1 μM. BX912 potently inhibits the growth of PC-3 cells in soft agar, displaying IC50 of 0.32 μM. [1]
In vivo試験
臨床試験
特集

プロトコル (参考用のみ)

キナーゼアッセイ: [1]

Kinase assays PDK1 is assayed in a direct kinase assay and a coupled assay format measuring PDK1- and PtdIns-3,4-P2-mediated activation of AKT2. For the coupled assay, the final assay mixture (60 μL) contained: 15 mM MOPS, pH 7.2, 1 mg/mL bovine serum albumin, 18 mM β-glycerol phosphate, 0.7 mM dithiothreitol, 3 mM EGTA, 10 mM MgOAc, 7.5 μM ATP, 0.2 μCi of [γ- 33P]ATP, 7.5 μM biotinylated peptide substrate (biotin-ARRRDGGGAQPFRPRAATF), 0.5 μL of PtdIns-3,4-P2-containing phospholipid vesicles, 60 pg of purified recombinant human PDK1, and 172 ng of purified recombinant human AKT2. After incubation for 2 hours at room temperature, the biotin-labeled peptide is captured from 10 μL of the assay mixture on streptavidin-coated SPA beads, and product formation is measured by scintillation proximity in a Wallac MicroBeta counter. The product formed is proportional to the time of incubation and to the amount of PDK1 and inactive AKT2 added. PDK1 is added at suboptimal levels so that the assay could sensitively detect inhibitors of AKT2 activation as well as direct inhibitor BX912 of PDK1 or AKT2. To measure PDK1 activity directly, the final assay mixture (60 μL) contained 50 mM Tris-HCl, pH 7.5, 0.1 mM EGTA, 0.1 mM EDTA, 0.1% β-mercaptoethanol, 1 mg/mL bovine serum albumin, 10 mM MgOAc, 10 μM ATP, 0.2 μCi of [γ-33P]ATP, 7.5 μM substrate peptide (H2N-ARRRGVTTKTFCGT), and 60 ng of purified recombinant human PDK1. After 4 hours at room temperature, 25 mM EDTA is added and a portion of the reaction mixture on P81 phosphocellulose paper is spotted. The filter paper is washed three times with 0.75% phosphoric acid and once with acetone. After drying, the filter-bound labeled peptide is quantified using a phosphorimager.

細胞アッセイ: [1]

細胞株 MDA-468, MDA-453
濃度 0.001-1 μM
反応時間 72 hours
実験の流れ Cells such as MDA-468, MDA-453 are seeded at a low density (1.5-3 × 103 cells/well, 0.1 mL/well, 96-well plates) and are incubated overnight. BX912 treatments are made by adding 10 μL/well of the compound in 1% dimethyl sulfoxide and growth medium (final concentration of dimethyl sulfoxide, 0.1%), followed by brief shaking. Treated cells are incubated for 72 hours, and viability is measured by the addition of 10 μL of the metabolic dye WST-1. The WST-1 signal is read in a plate reader at 450 nm, and a no cell, or zero time cell, background is subtracted to calculate the net signal.

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDogMonkeyBaboon
Weight (kg)0.020.151.80.40.0810312
Body Surface Area (m2)0.0070.0250.150.050.020.50.240.6
Km factor361285201220
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

参考

化学情報

Download BX-912 SDF
分子量 471.35
化学式

C20H23BrN8O

CAS No. 702674-56-4
保管 3年-20℃
2年-80℃in solvent
別名 N/A
溶解度 (25°C) * In vitro DMSO 94 mg/mL (199.42 mM)
Ethanol 94 mg/mL (199.42 mM)
Water <1 mg/mL
In vivo 30% PEG400+0.5% Tween80+5% propylene glycol 30 mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
化学名 N-(3-(4-(2-(1H-imidazol-5-yl)ethylamino)-5-bromopyrimidin-2-ylamino)phenyl)pyrrolidine-1-carboxamide

文献中の引用 (3)

技術サポート&よくある質問(FAQ)

ストックの作り方、阻害剤の保管する方法、細胞実験や動物実験に注意すべきな点を全部含めており、製品を取扱う時よくあった質問に対して取扱説明書でお答えいたします。

電話番号: +1-832-582-8158 Ext:3月曜日〜金曜日 9:00 AM–5:00 PM (米国中部標準時)

他の質問がある場合は、お気軽くお問合せください。

* 必須

Related PDK-1 阻害剤

  • CHIR-99021 (CT99021)

    CHIR-99021 (CT99021)は一種のGSK-3αとGSK-3β抑制剤で、IC50値が10 nM と6.7 nMに分かれます。

  • Dorsomorphin (Compound C, BML-275)

  • MHY1485

    MHY1485は一種の有効的で、細胞浸透性 mTOR 活性剤で、オートファジー(autophagy)も有効に抑制します。

  • Afuresertib (GSK2110183)

    Afuresertib (GSK2110183)は一種の有効的で、経口生物利用可能なAkt抑制剤で、Akt1、Akt2とAkt3に作用する時のKi値が0.08 nM、2 nMと2.6 nMそれぞれに分かれます。臨床2期。

  • OSU-03012 (AR-12)

    OSU-03012 (AR-12)は有効的に再編PDK-1を抑制、IC50が5µMになる。

    Features:A derivative of celecoxib with 10-fold greater antitumor activity, but lacks celecoxib's COX-2 inhibitory activity.

  • BX-795

    BX-795 は強い、比較的、具体的なtbk1とIKKεキナーゼ阻害剤、IC50 がそれぞれ 6 nM と 41 nM。

  • GSK2334470

    GSK2334470 is a novel and highly specific inhibitor of PDK1 with IC50 of ~10 nM.

  • Rapamycin (Sirolimus)

    Rapamycin (Sirolimus)は一種の特定なmTOR 抑制剤で、HEK293細胞中でIC50 値が約0.1 nMです。

  • MK-2206 2HCl

    MK-2206 2HCl は一種の高選択性のAkt1/2/3抑制剤で、無細胞試験でIC50値が8 nM/12 nM/65 nMそれぞれに分かれて、250種類他のタンパク質キナーゼに抑制活性を表しません。臨床2期。

    Features:The first allosteric small molecule inhibitor of Akt to enter clinical development.

最近チェックしたアイテム

Tags: BX-912を買う | BX-912供給者 | BX-912を購入する | BX-912費用 | BX-912生産者 | オーダーBX-912 | BX-912代理店
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
お問い合わせ